Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | VAXCYTE INC PCVX | RA CAPITAL MANAGEMENT L.P. | 12,649,728 9.990% | 2,964,649 (+30.61%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | VERONA PHARMA PLC SPONSORED AD VRNA | RA CAPITAL MANAGEMENT L.P. | 8,460,090 9.990% | 956,114 (+12.74%) | Filing History |
| 2024-11-13 6:04 pm Purchase | 2024-11-08 | 13D | TYRA BIOSCIENCES INC TYRA | RA CAPITAL MANAGEMENT L.P. | 10,677,140 21.100% | 586,069 (+5.81%) | Filing History |
| 2024-11-12 4:15 pm Purchase | 2024-11-04 | 13G | BRIGHT MINDS BIOSCIENCES INC C DRUG | RA CAPITAL MANAGEMENT L.P. | 460,829 6.600% | 460,829 (New Position) | Filing History |
| 2024-11-06 5:41 pm Purchase | 2024-10-30 | 13G | GLYCOMIMETICS INC GLYC | RA CAPITAL MANAGEMENT L.P. | 63,830 9.900% | 63,830 (New Position) | Filing History |
| 2024-11-06 4:15 pm Purchase | 2024-10-30 | 13G | ENSYSCE BIOSCIENCES INC PA ENSC | RA CAPITAL MANAGEMENT L.P. | 98,400 9.900% | 98,400 (New Position) | Filing History |
| 2024-11-05 4:17 pm Purchase | 2024-10-29 | 13G | ELEDON PHARMACEUTICALS INC ELDN | RA CAPITAL MANAGEMENT L.P. | 3,566,338 6.100% | 3,566,338 (New Position) | Filing History |
| 2024-11-04 4:39 pm Purchase | 2024-10-28 | 13D | SEPTERNA INC SEPN | RA CAPITAL MANAGEMENT L.P. | 6,995,858 15.800% | 6,995,858 (New Position) | Filing History |
| 2024-10-31 4:17 pm Purchase | 2024-10-24 | 13G | MONOPAR THERAPEUTICS INC MNPR | RA CAPITAL MANAGEMENT L.P. | 511,207 9.700% | 511,207 (New Position) | Filing History |
| 2024-10-22 5:11 pm Sale | 2024-10-18 | 13D | TYRA BIOSCIENCES INC TYRA | RA CAPITAL MANAGEMENT L.P. | 10,091,071 19.990% | -384,418 (-3.67%) | Filing History |
| 2024-10-22 4:17 pm Sale | 2024-10-18 | 13D | JANUX THERAPEUTICS INC JANX | RA CAPITAL MANAGEMENT L.P. | 10,443,181 19.990% | -299,812 (-2.79%) | Filing History |
| 2024-10-07 4:16 pm Purchase | 2024-09-27 | 13G | BIOAGE LABS INC BIOA | RA CAPITAL MANAGEMENT L.P. | 2,210,589 6.200% | 2,210,589 (New Position) | Filing History |
| 2024-10-01 5:47 pm Purchase | 2024-09-27 | 13D | WAVE LIFE SCIENCES LTD WVE | RA CAPITAL MANAGEMENT L.P. | 25,414,165 16.000% | 8,144,354 (+47.16%) | Filing History |
| 2024-09-23 4:17 pm Purchase | 2024-09-16 | 13D | BICARA THERAPEUTICS INC BCAX | RA CAPITAL MANAGEMENT L.P. | 6,955,993 12.800% | 6,955,993 (New Position) | Filing History |
| 2024-09-16 9:35 pm Purchase | 2024-09-12 | 13D | JANUX THERAPEUTICS INC JANX | RA CAPITAL MANAGEMENT L.P. | 10,742,993 19.990% | 149,598 (+1.41%) | Filing History |
| 2024-09-16 8:21 pm Purchase | 2024-09-12 | 13G | FULCRUM THERAPEUTICS INC FULC | RA CAPITAL MANAGEMENT L.P. | 10,229,099 19.300% | 4,684,883 (+84.50%) | Filing History |
| 2024-09-03 4:18 pm Unchanged | 2024-08-29 | 13D | ARTIVA BIOTHERAPEUTICS INC ARTV | RA CAPITAL MANAGEMENT L.P. | 9,853,302 40.600% | 0 (Unchanged) | Filing History |
| 2024-08-23 4:16 pm Purchase | 2024-08-13 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA CAPITAL MANAGEMENT L.P. | 967,299 9.990% | 967,299 (New Position) | Filing History |
| 2024-08-23 4:16 pm Sale | 2024-08-21 | 13G | FULCRUM THERAPEUTICS INC FULC | RA CAPITAL MANAGEMENT L.P. | 5,544,216 9.990% | -6,065,488 (-52.24%) | Filing History |
| 2024-08-13 5:40 pm Sale | 2024-08-09 | 13G | AN2 THERAPEUTICS INC ANTX | RA CAPITAL MANAGEMENT L.P. | 1,999,997 6.700% | -3,551,298 (-63.97%) | Filing History |